Stock NGNE NEUROGENE INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Neurogene Inc.

Equities

NGNE

US64135M1053

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
33.4 USD +11.48% Intraday chart for Neurogene Inc. +9.11% +72.34%
Apr. 29 Leerink Partners Starts Neurogene With Outperform Rating, $46 Price Target MT
Mar. 22 North American Morning Briefing : Stocks Struggle After New Records DJ

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Leerink Partners Starts Neurogene With Outperform Rating, $46 Price Target
MT
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting
BU
North American Morning Briefing : Stocks Struggle After New Records
DJ
William Blair Initiates Neurogene With Outperform Rating
MT
Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates
BU
Neurogene Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
North American Morning Briefing : Inflation -2-
DJ
Neurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial
BU
Neurogene Inc. Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial
CI
Neurogene to Participate in Upcoming Investor Conferences
BU
Neurogene Inc. Appoints Donna Cochener as Senior Vice President, General Counsel
CI
Neurogene Inc. Appoints Julie Jordan as Chief Medical Officer
CI
Neurogene Names Julie Jordan as Chief Medical Officer
MT
Neurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical Officer
BU
Neurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical Officer
CI
HC Wainwright Starts Neurogene With Buy Rating, $45 Price Target
MT
Stifel Starts Coverage on Neurogene with Buy Rating, $31 Price Target
MT
Neurogene Announces Business Update and 2024 Outlook
BU
Neurogene Announces Business Update and 2024 Outlook
CI
Neurogene Announces Closing of Merger with Neoleukin Therapeutics and Concurrent Private Placement of $95 Million
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NGNE Stock
  4. News Neurogene Inc.